Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, May 3, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Mathew Blackman Maintained (TNDM) at Strong Buy with Increased Target to $45 on, May 3rd, 2024
Mathew Blackman of Stifel, Maintained "Tandem Diabetes Care, Inc." (TNDM) at Strong Buy with Increased Target from $40 to $45 on, May 3rd, 2024.
Mathew has made no other calls on TNDM in the last 4 months.
There are 3 other peers that have a rating on TNDM. Out of the 3 peers that are also analyzing TNDM, 2 agree with Mathew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Joanne Wuensch of "Citigroup" Maintained at Hold with Increased Target to $38 on, Wednesday, April 3rd, 2024
- Rick Wise of "Stifel" Maintained at Hold with Increased Target to $24 on, Monday, February 5th, 2024
This is the rating of the analyst that currently disagrees with Mathew
- Mike Kratky of "Leerink Partners" Upgraded from Hold to Buy and Increased Target to $45 on, Thursday, April 25th, 2024
